# Jan Witowski

> Jan Witowski is the co-founder and CEO of Ataraxis AI, a New York precision-medicine company building AI models that read cancer tissue to predict how a patient's disease will behave and which treatments will help. A physician-scientist with an MD and PhD, he spent a decade in medical imaging research at Harvard, Massachusetts General Hospital, and NYU Langone before spinning Ataraxis out of NYU in 2023. The company's first product, Ataraxis Breast, is billed as the first AI-native prognostic and predictive test for breast cancer, and it raised a $20.4 million Series A in 2025 led by AIX Ventures.

- **Role:** Co-founder & CEO at Ataraxis AI
- **Organizations:** Ataraxis AI, NYU Langone Health, Harvard Medical School, Massachusetts General Hospital
- **From:** Poland
- **Nationality:** Polish
- **Education:** MD, PhD, Medical school and doctoral training (Poland), Research fellow, Harvard Medical School / Massachusetts General Hospital, Postdoctoral researcher, NYU Langone Health
- **Known for:** Co-founded and leads Ataraxis AI, a precision-medicine company building AI world models for oncology, Shipped Ataraxis Breast, billed as the first AI-native prognostic/predictive test for breast cancer, Oversaw development of Kestrel, a foundation model for digital pathology

## Career timeline

- **2010s** — Trained as a physician-scientist in Poland, earning an MD and a PhD
- **2010s** — Research fellow at Harvard Medical School and Massachusetts General Hospital
- **2019-2022** — Postdoctoral researcher at NYU Langone Health, leading AI and medical imaging projects
- **2022** — Co-founded Ataraxis AI with Krzysztof Geras
- **2023** — Spun Ataraxis out of NYU and raised a Seed round
- **2024** — Developed and clinically validated Ataraxis Breast and the Kestrel pathology foundation model; company launched publicly
- **2025** — Raised $20.4 million Series A led by AIX Ventures

## Achievements

- Co-founded and leads Ataraxis AI, a precision-medicine company building AI world models for oncology
- Shipped Ataraxis Breast, billed as the first AI-native prognostic/predictive test for breast cancer
- Oversaw development of Kestrel, a foundation model for digital pathology
- Ran an 8,000-patient retrospective clinical study showing AI can rival or beat molecular diagnostics
- Raised a $20.4 million Series A (2025) led by AIX Ventures with Founders Fund, Thiel Bio, Obvious Ventures and Giant Ventures
- Over a decade of medical image processing research at Harvard, MGH and NYU Langone

## Latest updates

- **2025-03** — Announced a $20.4 million Series A led by AIX Ventures to scale AI precision-medicine tests and launch commercially in the US.
- **2024-10** — Ataraxis AI publicly launched Ataraxis Breast and the Kestrel digital-pathology foundation model.

## Links

- Website: https://ataraxis.ai
- LinkedIn: http://www.linkedin.com/in/jan-witowski
- Twitter/X: https://x.com/janwitowski

---

Profile page: https://yespress.io/jan-witowski
Published by YesPress — https://yespress.io
Last updated: 2026-07-16